Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
1,439 stopped studies mapped to Leukemia and descendants · 87% state a reason
Over the 1,439 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT04161885 | A Study Evaluating Safety and Efficacy of Venetoclax in Combination With Azacitidine…(VIALE-T) | Phase 3 | terminated | Nov 13, 2019 | AbbVie | Strategic considerations | Sponsor / business decision |
| NCT04250051 | Ivosidenib and Combination Chemotherapy for the Treatment of IDH1 Mutant Relapsed or… | Phase 1 | terminated | Jan 31, 2020 | Northwestern University | Low accrual | Enrollment / accrual |
| NCT05224661 | Molecular Evaluation of AML Patients After Stem Cell Transplant to Understand Relapse…(MEASURE) | — | terminated | Feb 4, 2022 | Center for International Blood and Marrow Transplant Research | The study was stopped due to exhaustion of funding. No additional financial support could be… | Funding |
| NCT05413915 | Asciminib Used in Consolidation With Imatinib vs. Imatinib to Achieve TFR in CP-CML | Phase 3 | terminated | Jun 10, 2022 | Sarit Assouline | Insufficient patient accrual | Enrollment / accrual |
| NCT05515406 | A Study to Investigate the Safety, Tolerability, PK, PD, and Efficacy of ONO-7018 in… | Phase 1 | terminated | Aug 25, 2022 | Ono Pharmaceutical Co., Ltd. | The study was terminated due to a strategic decision to discontinue development. | Sponsor / business decision |
| NCT07123662 | γδ T Cell Therapy for Relapse Prevention in High-Risk AML Post-Transplant | Early Phase 1 | withdrawn | Aug 14, 2025 | Guangzhou Bio-gene Technology Co., Ltd | Due to corporate strategic adjustment. | Sponsor / business decision |
| NCT01135329 | Reduced-intensity, Related-donor Bone Marrow Transplantation Followed by High-dose… | Phase 2 | terminated | Jun 2, 2010 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | The stopping rule was met and hence the study was closed | Other (stated, no rule matched) |
| NCT01962636 | Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for… | N/A | terminated | Oct 14, 2013 | Masonic Cancer Center, University of Minnesota | No longer a research question to answer. | Other (stated, no rule matched) |
| NCT04824794 | GEN3014 Trial in Relapsed or Refractory Hematologic Malignancies | Phase 1 / Phase 2 | terminated | Apr 1, 2021 | Genmab | The sponsor has decided to discontinue further development of GEN3014 after a comprehensive review… | Sponsor / business decision |
| NCT06522373 | Phase I Trial of MT-0169 in CD38+ Acute Leukemia With Relapsed/Refractory or Measurable… | Phase 1 | withdrawn | Jul 26, 2024 | M.D. Anderson Cancer Center | PI Request | Other (stated, no rule matched) |
| NCT03246906 | Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity… | Phase 2 | terminated | Aug 11, 2017 | Fred Hutchinson Cancer Center | Study was terminated prior to enrolling protocol target accrual goal due to declining accrual and… | Safety / toxicity |
| NCT07585734 | Clinical Trial of CD38 Monoclonal Antibody Combined With Chemotherapy for T-Cell Acute… | Phase 1 / Phase 2 | withdrawn | May 14, 2026 | Institute of Hematology & Blood Diseases Hospital, China | drug-associated adverse reactions | Safety / toxicity |
| NCT02629692 | Safety and Anti-leukemic Activity of Vodobatinib (K0706) for Treatment of Ph+ CML… | Phase 1 / Phase 2 | terminated | Dec 14, 2015 | Sun Pharma Advanced Research Company Limited | Closed for administrative, non-safety-related reasons. | Safety / toxicity |
| NCT03808610 | Low-Intensity Chemotherapy and Venetoclax in Treating Patients With Relapsed or… | Phase 1 / Phase 2 | terminated | Jan 17, 2019 | M.D. Anderson Cancer Center | \<75% participation | Other (stated, no rule matched) |
| NCT06570915 | Daratumumab for T Cell ALL With MRD-positive After Standard Chemotherapy(T-ALL-2024) | Phase 2 | withdrawn | Aug 26, 2024 | Institute of Hematology & Blood Diseases Hospital, China | No eligeble patients | Other (stated, no rule matched) |
| NCT06662227 | Universal CAR-T Cells (REVO-UWD-19) for Refractory and Relapsed B-Cell Tumors | Early Phase 1 | suspended | Oct 28, 2024 | Wondercel Biotech (ShenZhen) | Because the implementation of the new regulation policy by the Chinese authority | Other (stated, no rule matched) |
| NCT07498465 | A Study to Find the Highest Dose of SNDX-5613 (Revumenib) as a Treatment Option After… | Phase 1 | withdrawn | Mar 27, 2026 | Children's Oncology Group | Other - Protocol moved to Withdrawn | Other (stated, no rule matched) |
| NCT04639024 | ADCT-301 in Patients With R/R AML, MDS, or MDS/MPN | Phase 2 | terminated | Nov 20, 2020 | Gwynn Long, M.D. | ADCT is reallocating all resources to the phase III program. | Other (stated, no rule matched) |
| NCT05268003 | A Phase II Study of the Combination of Ponatinib With Mini-hyper CVD Chemotherapy and… | Phase 2 | terminated | Mar 7, 2022 | M.D. Anderson Cancer Center | \< 75% participation | Other (stated, no rule matched) |
| NCT03878199 | Testing the Effect of Taking Ruxolitinib and CPX-351 in Combination for the Treatment of… | Phase 1 / Phase 2 | terminated | Mar 18, 2019 | Ohio State University Comprehensive Cancer Center | The study was originally planned to assess four escalating DLs of ruxolitinib (upto 40 mg twice… | Enrollment / accrual |
| NCT04435691 | Magrolimab, Azacitidine, and Venetoclax for the Treatment of Acute Myeloid Leukemia | Phase 1 / Phase 2 | terminated | Jun 17, 2020 | M.D. Anderson Cancer Center | 75% \> Participants | Other (stated, no rule matched) |
| NCT05607199 | A First in Human Study of AUR 103 Calcium to Evaluate Safety, Pharmacokinetics and…(BHARAT-1) | Phase 1 | terminated | Nov 7, 2022 | Aurigene Discovery Technologies Limited | Patient recruitment problems. | Enrollment / accrual |
| NCT03856216 | Inotuzumab Ozogamicin and Chemotherapy in Treating Patients With Leukemia or Lymphoma… | Phase 2 | terminated | Feb 27, 2019 | M.D. Anderson Cancer Center | \<75% participation | Other (stated, no rule matched) |
| NCT05263271 | Gentulizumab in Relapsed/Refractory Acute Myelogenous Leukemia or Myelodysplastic Syndrome | Phase 1 | terminated | Mar 2, 2022 | Changchun GeneScience Pharmaceutical Co., Ltd. | Adjusted the product development strategy. | Sponsor / business decision |
| NCT01366612 | Fludarabine and Busulfan vs. Fludarabine, Busulfan and Total Body Irradiation(FLUBUTBI) | Phase 3 | terminated | Jun 6, 2011 | Hackensack Meridian Health | Lack of Accrual | Enrollment / accrual |
| NCT02333162 | Intensity Modulated Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in… | Phase 1 | suspended | Jan 7, 2015 | University of Chicago | Enrollment on hold pending amendment | Enrollment / accrual |
| NCT03150004 | Efficacy and Pharmacogenomics of Cladribine Based Salvage Chemotherapy in Patients With… | Phase 2 | terminated | May 11, 2017 | Medical College of Wisconsin | No longer have funding support to complete the pharmacogenetics component. | Funding |
| NCT05933070 | A Phase I Open-Label Dose Escalation Study of Intravenous INKmune In Patients With MDS or…(LAUREL) | Phase 1 | terminated | Jul 6, 2023 | Inmune Bio, Inc. | Slow/low Enrollment | Enrollment / accrual |
| NCT06171152 | Study of Liraglutide (A Weight Loss Drug) in High Risk Obese Participants With Cognitive… | Early Phase 1 | suspended | Dec 14, 2023 | University of Chicago | Study pending amendment | Other (stated, no rule matched) |
| NCT06563804 | A Study to Evaluate S227928 as a Single Agent and in Combination With Venetoclax in… | Phase 1 / Phase 2 | terminated | Aug 21, 2024 | Servier Bio-Innovation LLC | Sponsor decision | Sponsor / business decision |
| NCT04278768 | Dose Escalation/ Expansion Study of CA-4948 as Monotherapy in Patients With Acute… | Phase 1 / Phase 2 | suspended | Feb 20, 2020 | Curis, Inc. | Dosing completed in all cohorts. Planning underway for potential additional patient cohorts. | Other (stated, no rule matched) |
| NCT03922100 | Study of NMS-03592088 in Patients With Relapsed or Refractory AML or CMML | Phase 1 / Phase 2 | terminated | Apr 19, 2019 | Nerviano Medical Sciences | Study stopped due to strategic reasons. The decision is not based on specific safety findings as… | Safety / toxicity |
| NCT05275439 | Phase 1 Study of Shattuck Labs (SL)-172154 in Subjects With MDS or AML | Phase 1 | terminated | Mar 11, 2022 | Shattuck Labs, Inc. | Development discontinued | Other (stated, no rule matched) |
| NCT03547115 | A Study of Voruciclib Alone or in Combination With Venetoclax in Subjects With B-Cell… | Phase 1 | terminated | Jun 6, 2018 | MEI Pharma, Inc. | Business reasons, not related to safety or efficacy results. | Safety / toxicity |
| NCT05909527 | A Clinical Study of CAR-T Treating Relapsed or Refractory T Cell Lymphoblastic Acute… | Phase 1 / Phase 2 | withdrawn | Jun 18, 2023 | Guangzhou Bio-gene Technology Co., Ltd | Due to corporate strategic adjustment. | Sponsor / business decision |
| NCT04347616 | Natural Killer-cell Therapy for Acute Myeloid Leukemia(NK4AML) | Phase 1 / Phase 2 | terminated | Apr 15, 2020 | Radboud University Medical Center | Stop funding | Funding |
| NCT04953312 | Calprotectin, a Biomarker of COVID-19 Severity (CALPRO)(CALPRO) | N/A | withdrawn | Jul 7, 2021 | Assistance Publique - Hôpitaux de Paris | Abandonment of the study project | Other (stated, no rule matched) |
| NCT06626633 | 2321GCCC: CRD3874-SI in Patients With Relapsed/Refractory AML | Phase 1 | suspended | Oct 4, 2024 | University of Maryland, Baltimore | Pharmaceutical Company withdrew support and investigational product | Sponsor / business decision |
| NCT03404193 | Venetoclax and Decitabine in Treating Participants With Relapsed/Refractory Acute Myeloid… | Phase 2 | terminated | Jan 19, 2018 | M.D. Anderson Cancer Center | \<75% participation | Other (stated, no rule matched) |
| NCT03772925 | Pevonedistat and Belinostat in Treating Patients With Relapsed or Refractory Acute… | Phase 1 | terminated | Dec 12, 2018 | National Cancer Institute (NCI) | Drug supply issues | Drug supply |
| NCT03514017 | Ibrutinib and PD-1 Blockade in High Risk Lymphocytic Leukemia | Phase 2 | terminated | May 2, 2018 | H. Lee Moffitt Cancer Center and Research Institute | Funding unavailable | Funding |
| NCT04216563 | ABL001 for the Treatment of Chronic Myeloid Leukemia in Patients Who Are on Therapy With… | Phase 2 | terminated | Jan 2, 2020 | M.D. Anderson Cancer Center | 75% \< Participants, Administrativley Complete | Other (stated, no rule matched) |
| NCT03953326 | HeartPhone Cancer Survivors Trial 2019 | Phase 1 / Phase 2 | terminated | May 16, 2019 | Penn State University | Futility in recruitment | Efficacy / futility |
| NCT05170828 | Cryopreserved MMUD BM With PTCy for Hematologic Malignancies | Phase 1 | withdrawn | Dec 28, 2021 | Ossium Health, Inc. | Change in Study Design | Other (stated, no rule matched) |
| NCT04964505 | Uproleselan, Azacitidine, and Venetoclax for the Treatment of Treatment Naive Acute… | Phase 1 | terminated | Jul 16, 2021 | Brian Jonas | Sponsor decision | Sponsor / business decision |
| NCT04817761 | SPARK-ALL: Calaspargase Pegol in Adults With ALL | Phase 2 / Phase 3 | terminated | Mar 26, 2021 | Institut de Recherches Internationales Servier | Sponsor decision | Sponsor / business decision |
| NCT03467386 | Total Marrow and Lymphoid Irradiation Before Donor Transplant and Cyclophosphamide in… | Phase 1 | suspended | Mar 16, 2018 | City of Hope Medical Center | accrual goal | Enrollment / accrual |
| NCT04328714 | Interferon γ-Primed Mesenchymal Stromal Cells as Prophylaxis for Acute Graft v Host… | Phase 1 | terminated | Mar 31, 2020 | Edwin Horwitz | Study was suspended pending renovation and reopening of the facility manufacturing the study… | Drug supply |
| NCT03913559 | Inotuzumab Ozogamicin for Children With MRD Positive CD22+ Lymphoblastic Leukemia | Phase 2 | terminated | Apr 12, 2019 | St. Jude Children's Research Hospital | Closed due to slow accrual | Enrollment / accrual |
| NCT04160052 | Venetoclax and Azacitidine for the Treatment of High-Risk Recurrent or Refractory… | Phase 1 / Phase 2 | terminated | Nov 12, 2019 | M.D. Anderson Cancer Center | \<75% participation | Other (stated, no rule matched) |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 22 days agoSource updated Jun 4, 2026source: clinicaltrials